Viking Therapeutics Stock Falls to $37.48 – Obesity Pipeline in Focus

Shares of Viking Therapeutics Inc. (ticker: VKTX) closed at $37.48 on July 1, 2026, declining 3.92 percent from the previous trading day. The US biotech company is currently conducting Phase 3 trials for its leading obesity therapeutic.

Volatile Price Movement in Second Quarter 2026

Viking Therapeutics shares showed significant fluctuations in recent months. On June 4, 2026, the stock stood at $29.78 and recorded a gain of 1.53 percent versus the previous day. On April 6, 2026, the stock closed at $33.93 with a decline of 2.5 percent.

The price movements reflect the typical profile of a clinical biotech company without approved products. Viking Therapeutics develops medications for metabolic diseases and is advancing its key candidate through late-stage clinical testing.

Phase 3 Trials for Obesity Therapeutic Underway

The company is conducting Phase 3 trials for its anti-obesity candidate. Phase 3 trials are large-scale clinical studies conducted immediately before regulatory approval decisions and are designed to demonstrate the efficacy and safety of a drug in a large patient population.

The obesity market has experienced strong growth for years, driven by new drug classes such as GLP-1 receptor agonists. Established pharmaceutical companies such as Novo Nordisk and Eli Lilly currently dominate the segment with approved products.

Market Observers Discuss Long-Term Potential

Analysts discussed in June 2026 whether Viking Therapeutics below $35 represents a buying opportunity. The assessment was based on the assumption that ongoing trials proceed as planned and deliver positive results.

In April 2026, market observers addressed the company's long-term perspective. Viking Therapeutics could develop into a player in the obesity market, though further development depends on clinical trial results and regulatory approvals. Potential obstacles were also mentioned, though without specific details.

Risk Profile of Clinical Biotech Companies

Biotech companies without approved products carry a high risk profile. Success depends largely on clinical trial results, which can be positive or negative. Failure in late-stage trials typically leads to sharp stock declines.

Viking Therapeutics currently generates no revenues from product sales and relies on capital market financing. Valuation is based on expectations regarding future approvals and market potential of pipeline candidates.